Dr.Huihui Zeng
Professor, PhD supervisor,
School of Pharmaceutical Science, Peking University
Principal Investigator,
State Key Laboratory of Natural and Biomimetic Drugs,
School of Pharmaceutical Science, Peking University
Principal Investigator,
Tianjin International Joint Academy of Biotechnology & Medicine (TJAB)
Leading Talent,
Wuhan East Lake High-tech Zone, “3551 Talent Plan” 3rd round
Resume:
1983-1986: Master, Department of Chemistry, Wuhan University
1991-1994: PhD in Medicinal Chemistry, School of Pharmaceutical Science, Peking University
1998-1999: Postdoc Fellowship, Department of Pharmacology, Seoul National University
From 1986, Dr. Huihui Zeng has been appointed as teaching assistant, assistant professor, and associate professor in Peking University. In 2006, she has been promoted to professor, PhD supervisor in the Department of Medicinal Chemistry, School of pharmaceutical science, Peking University. She is also the Principal Investigator (PI) of State Key Laboratory of Natural and Biomimetic Drugs in Peking University since 2007, and PI of Tianjin International Joint Academy of Biotechnology & Medicine since 2009. In Sep. 2010, she has been elected as the “Leading Talent” of Wuhan East Lake High-tech Zone “3551 Talent Plan” 3rd round.
Research Summary:
1.1 Research Fields
1. Research and Development of novel chemical drugs
2. Synthesis and Biological activity Research on organo-selenium compound
3. Synthesis and Pharmaceutical Research on anti-tumor drug development
4. Research on thioredoxin reductase and tumor
1.2 Brief Summary
Dr. Zeng has established the theoretical system of ethaselen as a novel anti-cancer agent and inhibitor of thiordoxin reductase (TR). Her research has covered the synthetic chemistry, medicinal chemistry, biology, pharmacology, clinical oncology, and drug development on TR. Her laboratory is already at world-class level in TR related scientific works and drug development, from where more than 40 master/PhD have been graduated in recent years.
1.2.1 Thioredoxin reductase (TR) and Cancer research
Dr. Zeng’s lab is mainly focused on the study of TR-mediated cancer apoptotic pathway, cancer cell cycle progression, low-differentiated tumor growth and other related biological events. Zeng’s group has published more than 40 papers in peer-reviewed journals in related fields including Free Radic Biol Med.，Differentiation，and Cancer letters. These important works have strongly demonstrated the significant role of TR in tumorigenesis, which are broadly cited by many high-impact chemical and biological journals including Chem. Rev. (SCI：26.054), JBC (SCI：5.8), Seminars in Cancer Biology (SCI：7.99)and Mini-Reviews in Medicinal Chemistry (SCI：3.06).
1.2.2 Thioredoxin reductase (TR) activity as diagnostic biomarker in clinical oncology
Dr. Zeng’s lab has performed the high-throughput clinical studies on TR activity in different subpopulations of tumor patients in China, and developed TR activity detection kit for malignant tumor diagnosis in clinical trials (Journal of Medical Laboratory and Diagnosis (in press), 2012)
1.2.3 Thioredoxin reductase (TR) inhibitor development
Dr.Zeng’s group has guided the development of multiple biological inhibitors as anti-cancer drugs, which have got authorized international and domestic patent protections. The representative drug ethaselen has entered into clinical trials in China as “National Chemical 1.1 Drugs”.
1.3 Projects
1.3.1 Completed projects
1) In charge of development of novel anti-tumor drug (1.1, chemical); Ethaselen is approved for clinical trial by SFDA. (2007)
---- Clinical Approval Document No. -->
2) In charge of development of novel anti-tumor drug (1.1, chemical); Ethaselen (dispersible tablets) is approved for clinical trial by SFDA. (2007)
---- Clinical Approval Document No.
3) In charge of clinical study of TR-activity diagnostic detection kit; more than 2,000 clinical samples have been completed in three hospitals. (2011)
---- Clinical Approval Date: 11/02/2011
1.3.2 Ongoing projects
1) In charge of clinical study of novel anti-tumor drug (1.1, chemical) Ethaselen (dispersible tablets).
---- Resource: SFDA approved clinical projects: Clinical Approval Document No.
---- Start Date: July, 2008
2) In charge of development of novel anti-tumor drug (1.1, chemical) Ethaselen (injection).
---- Resource: National Major New Drug Project, Preclinical, 2009
---- Start Date: July, 2009
3) In charge of development of novel anti-pancreatic tumor drug (1.1, chemical) Wbselen.
---- Resource: National Major New Drug Project, Preclinical, 2009
---- Start Date: July, 2009
1.4 Selected Publications(2010-)
[1] Ethaselen: a potent mammalian thioredoxin reductase 1 inhibitor and novel organoselenium anticancer agent. Free Radic. Biol. Med. (SCI＞5.5) (2012) 52(5):898-908.
Lihui Wang, Zhiyu Yang, Jianing Fu, Hanwei Yin, Kun Xiong, Qiang Tan, Hongwei Jin, Jing Li, Tianyu Wang, Wanchen Tang, Jin Yin, Gaoxiong Cai, Mi Liu, Sebastian Kehr, Katja Beckec, Huihui Zeng
[2] Novel mechanism of ethaselen in poorly differentiated colorectal RKO cell growth inhibition:Simultaneous regulation of TrxR transcription,expression and enzyme activity. Differentiation (SCI＞3.0) (2011) 81(1):49-56.
Hanwei Yin, JingLi, KunXiong, LihuiWang, TianyuWang, QiangTan JianingFu, Xiaoyuan Ren, HuihuiZeng
[3] Thioredxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest. Invest New Drugs (SCI＞3.0) (2011) 29(4):627-36.
Jia-ning Fu, Jing Li, Qiang Tan, Han-wei Yin, Kun Xiong, Tian-yu Wang, Xiao-yuan Ren, Hui-hui Zeng
[4] Preparation of tri-block copolymer micelles loading novel organoselenium anticancer drug BBSKE and study of tissue distribution of copolymer micelles by imaging in vivo method. International Journal of Pharmaceutics (SCI＞3.0) (2010) 391(1-2):292-304.
Mi Liu, Jianing Fu, Jing Li, Lihui Wang, Qiang Tan, Xiaoyuan Ren, Zuofu Peng, Huihui Zeng
[5] Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo. Invest New Drugs (SCI＞3.0) (2010) 28(3):205-215.
Tan Q, Li J, Yin HW, Wang LH, Tang WC, Zhao F, Liu XM, Zeng HH.
